Domenica Rubino
Endocrinology, Diabetes & Metabolism · Arlington, VANPI 1639226236
Payments from drug & device makers
Across 1,412 payments — averaging $2095.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1.7M
- Boehringer Ingelheim$435K
- Novo Nordisk$299K
- Amgen$184K
- AstraZeneca$174K
- Boehringer Ingelheim International GmbH$41K
- plus $83K from 16 others
Across 3 payments — averaging $1527.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3K
- Amgen$2K
What the payments were for
- Consulting fees$288,50547%
- Speaking & faculty fees$135,12122%
- Travel & lodging$168,20628%
- Food & beverage$14,9662%
- Education$1,6840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 745 | $1,743,678 |
| Boehringer Ingelheim | 71 | $434,502 |
| Novo Nordisk | 280 | $299,248 |
| Amgen | 1 | $183,557 |
| AstraZeneca | 8 | $174,109 |
| Boehringer Ingelheim International GmbH | 111 | $40,763 |
| AbbVie | 16 | $18,047 |
| Regeneron | 35 | $16,116 |
| Boehringer Ingelheim France S.a.s. | 92 | $13,068 |
| Neurocrine Biosciences, Inc. | 9 | $12,867 |
| Lilly USA, LLC | 16 | $11,420 |
| Shionogi Inc | 3 | $3,360 |
| Ferring Pharmaceuticals AS | 1 | $3,210 |
| Eli Lilly | 8 | $2,024 |
| Novo Nordisk Health Care AG | 1 | $1,700 |
| F. Hoffmann-la Roche AG | 1 | $500 |
| Pfizer | 1 | $400 |
| IBSA Pharma Inc. | 4 | $81 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Corcept Therapeutics | 2 | $45 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kvk-tech, Inc. | 4 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,958,768 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $67,743 |
| OzempicSemaglutide | 20 | $32,790 |
| Metformin Hcl ErMetformin Hcl | 19 | $449 |
| Rosuvastatin Calcium | 13 | $119 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $11,420 | $67,74355 claims |
| Novo NordiskOzempic | $299,248 | $32,79020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Arlington
- Caroline HuangArlington$34K
- Thien-Giang Bach-HuynhArlington$8K
- Massoud SaberiniaArlington$8K
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.